Erschienen in:
01.12.2005 | Letter
Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast
verfasst von:
Junsuke Shimbo, Osamu Onodera, Keiko Tanaka, Shoji Tsuji
Erschienen in:
Clinical Rheumatology
|
Ausgabe 6/2005
Einloggen, um Zugang zu erhalten
Abstract
The authors studied eight cases of Churg-Strauss syndrome (CSS) associated with the use of pranlukast, a common cysteinyl leukotriene receptor antagonist (LTRA) in Japan. The patients who received pranlukast showed significantly increased peripheral blood eosinophil count, neurological disability scores, and poor responses to corticosteroid in comparison with those patients not receiving pranlukast. We suggest that preceding administration of pranlukast aggravates clinical presentations of CSS.